Dimension Therapeutics Inc.'s $20 million up-front gene therapy deal – with the potential for $232 million in milestone payments – comes less than a year after the company was founded and draws to the table Bayer Healthcare Pharmaceuticals Inc., which gains rights to "the strategic must-have for them to maintain an ongoing presence in the hemophilia A space," said Dimension's CEO and co-founder Thomas Beck.